Research Interests

Dr. Hayashi is Director of the Division of Pediatric Hematology/Oncology and an attending physician in Hematology/Oncology and General Pediatrics at St. Louis Children’s Hospital. Dr. Hayashi's research interest primarily focuses on issues regarding the long term effects of cancer therapy. His efforts examine the nature and spectrum of clinical conditions that effect childhood cancer survivors with the goal of developing interventions that will improve the outlook of this patient population. He is involved in both institutional and national efforts to gain insight in this rapidly evolving area of investigation and he also directs The Late Effects Clinic at St. Louis Children’s Hospital providing comprehensive care for patients afflicted with a broad scope of conditions.Dr. Hayashi's clinical interests also include bone marrow transplantation, Non-Hodgkin's Lymphoma and post-transplant lymphoproliferative disease (PTLD). He is actively involved in national trials advancing the treatment of patients in these areas.

Education

  • BS, Departmental Honors, Stanford University1982
  • MD, Washington Unversity School of Medicine1986

Training

  • Intern in Pediatrics, St. Louis Chiildren's Hospital1986 - 1987
  • Resident in Pediatrics , St. Louis Children's Hospital1987 - 1989
  • Fellowship in Pediatric Hematology/Oncology, The Johns Hopkins School of Medicine 1989 - 1992

Licensure and Board Certification

  • American Board of Pediatrics 1991
  • Pediatric Hematology/Oncology 1992
  • MO, Missouri Medical Licensure 1994

Honors

  • Departmental Honors, Department of Biology, Stanford University, Stanford California1982
  • Child Health Research Center Award1990 - 1992
  • Physicain Scientist Award1992 - 1997
  • Castle Connolly's America's Top Doctors in Cancer2005 - Pres
  • Castle Connolly's America's Top Doctors2006 - Pres
  • Legacy Award, National Children's Cancer Society2006
  • Medical Excellence Award, National Childrens Cancer Society2013

Selected Publications view all (69)


Publication Co-Authors

1.
Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders. Biol Blood Marrow Transplant. 2016. doi:10.1016/j.bbmt.2016.04.025  PMID:27164064 
2.
The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015. doi:10.1038/ng.3400  PMID:26457647 
3.
Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol. 2015. doi:10.1002/ajh.24183  PMID:26348869 
4.
Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015. doi:10.1016/j.bbmt.2015.08.023  PMID:26327632 
5.
A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant. 2015. doi:10.1038/bmt.2015.177  PMID:26237164 
6.
Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. Biol Blood Marrow Transplant. 2015. doi:10.1016/j.bbmt.2015.05.023  PMID:26033280 
7.
The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. Biol Blood Marrow Transplant. 2015. doi:10.1016/j.bbmt.2015.05.010  PMID:25981509 
8.
Neurocognitive outcomes and school performance in solid tumor cancer survivors lacking therapy to the central nervous system. J Pers Med. 2015;5(2):83-90. doi:10.3390/jpm5020083  PMID:25867598 
9.
Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin. Biol Blood Marrow Transplant. 2015. doi:10.1016/j.bbmt.2015.03.019  PMID:25840334